New clinical data showed that Lomecel-B™ improved cognitive function in multiple measures in a dose-response fashion Caregiver ratings documented improved quality of life in Lomecel-B™ treated patientsMRI Biomarker study data showed that Lomecel-B™ countered loss of brain volume in multiple areas associated with Alzheimer’s disease, reduced brain neuroinflammation and improved cerebral blood flow Overall results confirmed the drug product’s therapeutic potential in the treatment of mild Alzheimer’s disease and support further development MIAMI, Dec.

新的临床数据表明，Lomecel-B™以剂量反应方式在多种措施中改善认知功能护理人员评级记录了洛美塞尔B的生活质量改善™治疗患者的MRI生物标志物研究数据显示，Lomecel-B™与阿尔茨海默病相关的多个区域的脑容量减少，脑神经炎症减少和脑血流改善总体结果证实了该药物在治疗轻度阿尔茨海默病方面的治疗潜力，并支持进一步发展迈阿密，12月。

20, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announces additional new clinical and biomarker results from its Phase 2a CLEAR MIND trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease.

2023年2月20日（全球新闻通讯社）--Longeveron Inc.（纳斯达克：LGVN）（“Longeveron”或“公司”），一家临床阶段的生物技术公司，开发针对威胁生命和慢性衰老相关疾病的细胞疗法，如左心发育不全综合征（HLHS），阿尔茨海默氏病和衰老相关的虚弱，今天宣布了其研究产品Lomecel-B的2a期CLEAR MIND试验的其他新的临床和生物标志物结果™用于治疗轻度阿尔茨海默病。

The expanded data set reinforced the earlier top-line findings showing that the primary safety endpoint was met and provided further support for Lomecel-B’s positive benefit/risk profile. Additional analysis of cognitive function and daily living data consistently showed favorable results with Lomecel-B™ over placebo in a dose-response fashion, with administration of Lomecel-B™ associated with slowing and in some cases improving certain measurements of cognitive function (MoCA, MMSE).

扩展的数据集强化了早期的一线调查结果，表明主要安全终点得到了满足，并为Lomecel-B的积极收益/风险概况提供了进一步的支持。对认知功能和日常生活数据的进一步分析一致表明，使用Lomecel-B取得了良好的结果™以剂量反应方式优于安慰剂，并服用洛美塞尔B™与减慢和在某些情况下改善某些认知功能测量有关（MoCA，MMSE）。

New analyses of imaging data measured using MRI showed that administration of Lomecel-B™ was associated with reduced neuroinflammation assessed by Diffusion Tensor Imaging (DTI), and also appeared to counter loss in brain volume in areas associated with A.

对使用MRI测量的成像数据的新分析表明，服用洛美塞尔B™与扩散张量成像（DTI）评估的神经炎症减少有关，并且似乎可以抵消与A相关区域的脑容量损失。